Bethesda, MD's Northwest Biotherapeutics has watched as rivals Dendreon and ImmunoCellular have run into serious roadblocks with personalized cancer vaccines over the past year, but with a major Phase III study underway, the biotech believes it can change the narrative.
The cancer immunotherapy biotech Agenus has continued its march back from a big R&D setback earlier in the year, seeing its share price spike 36% this morning after posting positive results for a single-arm Phase II study of one of its brain cancer vaccines.
An investigative team at the University of Zurich says they have nailed down some clear proof-of-principle evidence in animal studies that a combination of interleukin-12 used in a combo immunotherapy approach offers a promising new avenue of research in tackling lethal cases of brain cancer.
A cellular pathway interaction that plays a role in repairing serious injuries may also be a promising target for preventing the spread of a deadly type of brain cancer, according to a new study.
Using a similar method they once used to treat breast cancer, researchers at UCLA are employing nanodiamonds to deliver cancer drugs to the brain, providing treatment for the particularly aggressive glioblastoma.
A new stem cell treatment that combines neural stem cells with chemo-radiotherapy drugs could provide a better way to combat glioblastoma, the most common and lethal form of adult brain cancer.
An experimental drug being developed by scientists at the Ohio State University Comprehensive Cancer Center can cross the blood-brain barrier, making it a promising novel treatment for deadly brain tumors.
There is no cure for the aggressive brain cancer glioblastoma, and even aggressive treatments have little effect. But researchers have homed in on a target enzyme that could help minimize the cancer's growth and possibly stop it altogether.
Researchers at the Moffitt Cancer Center in Tampa, FL, are tapping into nature to find the next potential treatment for brain tumors.
Roche took two steps forward and one step back on the Avastin front today, as investigators laid out a clear advantage in adding the therapy to chemo for cervical cancer while finding no survival advantage when adding it to first-line treatment of an aggressive form of brain cancer.